Servier’s $1.55 billion muscular dystrophy drug fails first major test
The company says its phase 3 Becker muscular dystrophy trial did not meet its primary or secondary endpoints.
TL;DR
- Servier said the phase 3 GRAND CANYON study of sevasemten did not meet its primary endpoint or secondary endpoints.
- The 18-month placebo-controlled trial evaluated the drug in Becker muscular dystrophy; Servier said its safety and tolerability profile remained favorable.
- Full results have not been released, and the company says it is analyzing the dataset alongside earlier clinical results.
Servier said sevasemten did not achieve a statistically significant benefit on the North Star Ambulatory Assessment in the phase 3 GRAND CANYON trial. The company also said the secondary endpoints were not met. [1]
The study was an 18-month global placebo-controlled trial in Becker muscular dystrophy. STAT reported that Servier acquired the drug from Edgewise Therapeutics in June for $1.55 billion upfront, with additional potential milestone payments. [1] [2]
Servier described the drug’s safety and tolerability profile as favorable, while noting that the result differed from findings in earlier studies, including the phase 2 CANYON trial. The company said it is conducting a comprehensive analysis of the trial data and prior clinical evidence. [1] [2]
The company has not yet presented the full results, so the reasons for the phase 3 outcome and its implications for the development program remain open. The available announcement reports topline findings rather than a complete peer-reviewed dataset. [1] [2]
Why it matters
A negative pivotal result changes the near-term evidence for a high-value rare-disease program. Until full data are released, researchers and developers cannot assess the size, causes, or subgroup pattern of the difference from earlier studies.
Editor's note
Topline company results; full trial data have not yet been presented.